The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Open accessAbstract
A main limitation of therapies that selectively target kinase signalling pathways is the emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the extracellular domain of epidermal growth factor receptor (EGFR), is effective in a subset of KRAS wild-type metastatic colorectal cancers. After an initial response, secondary resistance invariably ensues, thereby limiting the clinical benefit of this drug. The molecular bases of secondary resistance to cetuximab in colorectal cancer are poorly understood. Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers. Expression of mutant KRAS under the control of its endogenous gene promoter was sufficient to confer cetuximab resistance, but resistant cells remained sensitive to combinatorial inhibition of EGFR and mitogen-activated protein-kinase kinase (MEK). Analysis of metastases from patients who developed resistance to cetuximab or panitumumab showed the emergence of KRAS amplification in one sample and acquisition of secondary KRAS mutations in 60% (6 out of 10) of the cases. KRAS mutant alleles were detectable in the blood of cetuximab-treated patients as early as 10 months before radiographic documentation of disease progression. In summary, the results identify KRAS mutations as frequent drivers of acquired resistance to cetuximab in colorectal cancers, indicate that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression and suggest early initiation of a MEK inhibitor as a rational strategy for delaying or reversing drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients who initially respond to anti-EGFR develop acquired resistance within 12 to 18 months due to secondary mutations in KRAS genes, EGFR exodomain alteration, and clonal selection [9].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We and others previously reported that KRAS acquired mutations are responsible for secondary resistance to anti-EGFR therapies in CRC(22, 23).”
From EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. (2020) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“Patients who fail to respond to therapy initially exhibit intrinsic resistance, whereas those who relapse after initial response are associated with acquired resistance [9].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [9]
In the citing paper
“Emergence of KRAS amplification and acquisition of secondary KRAS mutations (G12C, G12D, G13D and Q61H) was detected as one mechanism of acquired resistance in metastatic CRC patients, who relapsed on cetuximab or panitumumab treatment (78, 79).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [78]
In the citing paper
“KRAS point mutations and gene copy number gains are responsible not only for primary but also for acquired resistance in 38–60 % of patients who relapse on cetuximab or panitumumab [37-39].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [38]
In the citing paper
“KRAS alterations could be identified noninvasively 5–10 months before radiographic disease progression by analyzing cell-free circulating tumor DNA (ctDNA) [37, 38].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [38]
In the citing paper
“however, the proof of principle that such an approach could complement tumor biopsy and provide an early warning of acquired resistance has been established [38, 41, 136].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [38]
In the citing paper
“To address these challenges, Mirati Therapeutics conducted high-resolution crystal structure analyses of compounds bound to mutant KRAS proteins, optimizing these compounds to develop MRTX1133, a non-covalent, selective inhibitor for KRAS G12D [60].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [60]
In the citing paper
“For instance, BRAF (V600E) and MAP2K1/MEK1 (K57T, K57N, I99_K104 deletion, and E102_I103 deletion) can also cause acquired drug resistance [94, 108–111].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [110]
In the citing paper
“By performing repeat biopsies and evaluating circulating tumor DNA, investigators observed the emergence of KRAS mutations as a resistance mechanism (Diaz et al., 2012; Misale et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Misale et al., 2012
In the citing paper
“non-invasive measures such as molecular interrogation of circulating tumor cells or plasma DNA may help capture the heterogeneity of resistance in patients, as was done to identify the development of KRAS mutations in colorectal cancers that acquire resistance to cetuximab (Diaz et al., 2012; Misale et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Misale et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationCirculating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationEGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,095
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Self-citationMolecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
Self-citationActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574
Cited by
Sorted by citations
Items 601–700 of 1,014
Cheng, X., Zhao, F., Ke, B., Chen, D., & Liu, F. (2023) · Cancers · doi:10.3390/cancers15215209 · Cited by 44
Tunneling Nanotubes Facilitate Intercellular Protein Transfer and Cell Networks Function
Turos-Korgul, L., Kolba, M. D., Chrościcki, P., Zieminska, A., & Piwocka, K. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.915117 · Cited by 44
Vidal, J., Fernández‐Rodríguez, C., Casadevall, D., Alfonso, P. G., Páez, D., Guix, M., Alonso, V., Cano, M. T., Santos, C., Durán, G., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1696 · Cited by 44
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
Patelli, G., Mauri, G., Tosi, F., Amatu, A., Bencardino, K. B., Bonazzina, E. F., Pizzutilo, E. G., Villa, F., Calvanese, G., Agostara, A. G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0079 · Cited by 44
Self-citationLewis, J. M., Heineck, D. P., & Heller, M. J. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1069709 · Cited by 44
Genomic Sequencing for Cancer Diagnosis and Therapy
Wang, L., & Wheeler, D. A. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-120811-171056 · Cited by 44
Lai, A. Z., Cory, S. M., Zhao, H., Gigoux, M., Monast, A., Guiot, M.-C., Huang, S., Tofigh, A., Thompson, C., Naujokas, M. A., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004839 · Cited by 44
Inamura, K., Song, M., Jung, S., Nishihara, R., Yamauchi, M., Lochhead, P. J., Qian, Z. R., Kim, S. A., Mima, K., Sukawa, Y., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv363 · Cited by 44
Natural and chemotherapy-induced clonal evolution of tumors
Ibragimova, M. K., Tsyganov, M. M., & Литвяков, Н. В. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917040022 · Cited by 44
Prieur, A., Cappellini, M., Habif, G., Lefranc, M., Mazard, T., Morency, E., Pascussi, J., Flacelière, M., Cahuzac, N., Vire, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0533 · Cited by 44
Lu, W., Fu, D., Kong, X., Huang, Z., Hwang, M., Zhu, Y., Chen, L., Jiang, K., Li, X., Wu, Y., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2786 · Cited by 44
Heyman, B. M., & Yang, Y. (2019) · Cancers · doi:10.3390/cancers11020191 · Cited by 43
Hirotsu, Y., Yokoyama, H., Amemiya, K., Hagimoto, T., Daimon, H., Hosaka, K., Oyama, T., Mochizuki, H., & Omata, M. (2019) · Cancer Science · doi:10.1111/cas.14155 · Cited by 43
Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer
Zhou, Q. X., Perakis, S. O., Ulz, P., Mohan, S., Riedl, J. M., Talakić, E., Lax, S., Tötsch, M., Höefler, G., Bauernhofer, T., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-0719-6 · Cited by 43
Li, Y., Eresen, A., Shangguan, J., Yang, J. Y., Benson, A. B., Yaghmai, V., & Zhang, Z. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03354-z · Cited by 43
Colorectal Cancer: From Genetic Landscape to Targeted Therapy
Bali, M. E., Bakkach, J., & Mechita, M. B. (2021) · Journal of Oncology · doi:10.1155/2021/9918116 · Cited by 43
Johnson, R. M., Qu, X., Lin, C.-F., Huw, L.-Y., Venkatanarayan, A., Sokol, E., Ou, F.-S., Ihuegbu, N., Zill, O. A., Kabbarah, O., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33172-5 · Cited by 42
Roosan, M. R., Mambetsariev, I., Pharaon, R. R., Fricke, J., Husain, H., Reckamp, K. L., Koczywas, M., Massarelli, E., Bild, A. H., & Salgia, R. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.04.016 · Cited by 42
Prioritizing therapeutic targets using patient-derived xenograft models
Lodhia, K. A., Hadley, A. M., Haluska, P., & Scott, C. L. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.03.002 · Cited by 42
Möhlendick, B., Bartenhagen, C., Behrens, B., Honisch, E., Raba, K., Knoefel, W. T., & Stoecklein, N. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067031 · Cited by 42
Cavalloni, G., Neia, C. P., Sassi, F. P., Chiorino, G., Sarotto, I., Aglietta, M., & Leone, F. (2016) · BMC Cancer · doi:10.1186/s12885-016-2136-1 · Cited by 42
Modeling Tumor Clonal Evolution for Drug Combinations Design
Zhao, B., Hemann, M. T., & Lauffenburger, D. A. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.02.001 · Cited by 42
Cannataro, V. L., Gaffney, S. G., Stender, C., Zhao, Z.-M., Philips, M. R., Greenstein, A. E., & Townsend, J. P. (2018) · Oncogene · doi:10.1038/s41388-017-0105-z · Cited by 43
Rowe, S. P., Luber, B. S., Makell, M., Brothers, P., Santmyer, J., Schollenberger, M. D., Quinn, H., Edelstein, D. L., Jones, F. S., Bleich, K. B., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12373 · Cited by 42
Tumour biomarkers—Tracing the molecular function and clinical implication
Lin, J., Ma, L., Zhang, D., Gao, J., Jin, Y., Han, Z., & Lin, D. (2019) · Cell Proliferation · doi:10.1111/cpr.12589 · Cited by 42
Takeda, K., Yamada, T., Takahashi, G., Iwai, T., Ueda, K., Kuriyama, S., Koizumi, M., Matsuda, A., Shinji, S., Ohta, R., et al. (2019) · Cancer Science · doi:10.1111/cas.14186 · Cited by 42
Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking
Cresswell, G. D., Nichol, D., Spiteri, I., Tari, H., Zapata, L., Heide, T., Maley, C. C., Magnani, L., Schiavon, G., Ashworth, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15047-9 · Cited by 42
Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma
Wang, L., Mo, S., Li, X., He, Y., & Yang, H. J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0073 · Cited by 42
Wang, S., Yeh, S., & Chen, P. (2021) · Cancers · doi:10.3390/cancers13102454 · Cited by 42
Božić, I., & Nowak, M. A. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042716-094839 · Cited by 42
Subgroup-Based Adaptive (SUBA) Designs for Multi-arm Biomarker Trials
Xu, Y., Trippa, L., Müller, P., & Ji, Y. (2014) · Statistics in Biosciences · doi:10.1007/s12561-014-9117-1 · Cited by 42
Towards clinically translatable NIR fluorescence molecular guidance for colonoscopy
Garcia-Allende, P. B., Glatz, J., Koch, M., Tjalma, J. J. J., Hartmans, E., van Scheltinga, A. G. T. T., Symvoulidis, P., van Dam, G. M., Nagengast, W. B., & Ntziachristos, V. (2013) · Biomedical Optics Express · doi:10.1364/boe.5.000078 · Cited by 42
Crystal structure of ERK2 G169D mutant
Yin, J., Jaiswal, B. S., & Wang, W. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6d5y/pdb · Cited by 42
Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
Ríos-Hoyo, A., Monzonís, X., Vidal, J., Linares, J., & Montagut, C. O. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1398419 · Cited by 41
Richiardone, E., Roumi, R. A., Lardinois, F., Giolito, M. V., Ambroise, J., Boidot, R., Drotleff, B., Ghesquière, B., Bellahcène, A., Bardelli, A., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217091 · Cited by 41
Self-citationUnderstanding resistance to targeted cancer drugs through loss of function genetic screens
Berns, K., & Bernards, R. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.10.002 · Cited by 41
DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis
Png, C. W., Weerasooriya, M., Guo, J., James, S. J., Poh, H.-M., Osato, M., Flavell, R. A., Dong, C., Yang, H. H., & Zhang, Y. (2015) · Oncogene · doi:10.1038/onc.2015.74 · Cited by 41
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer
Sameen, S., Barbuti, R., Milazzo, P., Cerone, A., Re, M. D., & Danesi, R. (2015) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2015.10.019 · Cited by 41
RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer
Waring, P. M., Tie, J., Maru, D. M., & Karapetis, C. S. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.10.006 · Cited by 41
Alcaide, M., Cheung, M. C., Bushell, K. R., Arthur, S. E., Wong, H., Karasinska, J. M., Renouf, D. J., Schaeffer, D. F., McNamara, S., du Tertre, M. C., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.09.007 · Cited by 41
Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer
Elgendy, M., Fusco, J. P., Segura, V., Lozano, M. D., Minucci, S., Echeveste, J. I., Gúrpide, A., Andueza, M., Melero, I., Sanmamed, M. F., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32256 · Cited by 41
Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer
Léonce, C., Saintigny, P., & Ortiz‐Cuaran, S. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0038 · Cited by 41
Novel Secondary Somatic Mutations in Ewing's Sarcoma and Desmoplastic Small Round Cell Tumors
Jiang, Y., Subbiah, V., Jankú, F., Ludwig, J. A., Naing, A., Benjamin, R. S., Brown, R. E., Anderson, P. M., & Kurzrock, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093676 · Cited by 41
Biomarker-driven patient selection for early clinical trials
Dienstmann, R., Rodon, J. A., & Tabernero, J. M. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835ff3cb · Cited by 40
Myers, M. B., Banda, M., McKim, K. L., Wang, Y., Powell, M. J., & Parsons, B. L. (2016) · Neoplasia · doi:10.1016/j.neo.2016.03.002 · Cited by 40
Kim, N., Cho, D., Kim, H., Kim, S., Cha, Y., Greulich, H. E., Bass, A. J., Cho, H., & Cho, J. (2019) · International Journal of Cancer · doi:10.1002/ijc.32499 · Cited by 40
Circulating Tumor DNA and Hepatocellular Carcinoma
Yang, J. D., Liu, M., & Kisiel, J. B. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1688503 · Cited by 40
Lu, H., Zhang, H., Weng, M., Zhang, J., Jiang, N., Cata, J. P., Ma, D., Chen, W., & Miao, C. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30161 · Cited by 40
Duffy, M. J., & Crown, J. P. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010099 · Cited by 40
Raghav, K. P. S., Ou, F., Venook, A. P., Innocenti, F., Sun, R., Lenz, H., & Kopetz, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00365 · Cited by 40
Overcoming Resistance to Targeted Therapies in Cancer
Redmond, K. L., Papafili, A., Lawler, M., & Schaeybroeck, S. V. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.028 · Cited by 39
Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA
Diaz, L. A., Sausen, M., Fisher, G. A., & Velculescu, V. E. (2013) · Oncotarget · doi:10.18632/oncotarget.1486 · Cited by 39
Saber, A., Hiltermann, T. J. N., Kok, K., Terpstra, M. M., de Lange, K., Timens, W., Groen, H. J. M., & van den Berg, A. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw128 · Cited by 39
Peeters, M., Price, T. J., Taı̈eb, J., Geißler, M., Rivera, F., Canon, J.-L. R., Pentheroudakis, G. E., Koukakis, R., Burdon, P., & Siena, S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0165-z · Cited by 39
Self-citationGuo, M., You, C., & Dou, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.109 · Cited by 39
Peeters, M., Price, T. J., Boedigheimer, M. J., Kim, T. W., Ruff, P., Gibbs, P., Thomas, A., Demonty, G., Hool, K., & Ang, A. L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2072 · Cited by 39
Varshavi, D., Varshavi, D., McCarthy, N., Veselkov, K., Keun, H. C., & Everett, J. R. (2020) · Metabolomics · doi:10.1007/s11306-020-01674-2 · Cited by 41
Patelli, G., Vaghi, C., Tosi, F., Mauri, G., Amatu, A., Massihnia, D., Ghezzi, S., Bonazzina, E. F., Bencardino, K. B., Cerea, G., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00795-5 · Cited by 39
Self-citationTumor Heterogeneity in Breast Cancer
Badve, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-41761-5_9 · Cited by 39
Nishimura, R., Takita, J., Sato‐Otsubo, A., Kato, M., Koh, K., Hanada, R., Tanaka, Y., Kato, K., Maeda, D., Fukayama, M., et al. (2013) · Cancer Science · doi:10.1111/cas.12173 · Cited by 39
Dienstmann, R., Salazar, R., & Tabernero, J. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.91 · Cited by 38
Gutteridge, A., Rathbone, V. M., Gibbons, R., Bi, M., Archard, N., Davies, K. E. J., Brown, J., Plagnol, V., Pillay, N., Amary, F., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1146 · Cited by 38
The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
Tria, S. M., Burge, M. E., & Whitehall, V. L. J. (2023) · Cancers · doi:10.3390/cancers15082375 · Cited by 38
New structural and functional insight into the regulation of Ras
Kano, Y., Cook, J. D., Lee, J. E., & Ohh, M. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.006 · Cited by 38
Izar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 38
Napolitano, S., Ciardiello, D., Falco, V. D., Martini, G., Martinelli, E., Corte, C. M. D., Esposito, L., Famiglietti, V., Liello, A. D., Avallone, A., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34632 · Cited by 38
Asić, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.004 · Cited by 38
Tumour heterogeneity: principles and practical consequences
Stanta, G., Jahn, S. W., Bonin, S., & Höefler, G. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1987-9 · Cited by 38
AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors
Oliveira, R. J. D. S., Melendez, M. E., Martinho, O., Zanon, M. F., Viana, L. D. S., Carvalho, A. L., & Reis, R. M. (2017) · Oncotarget · doi:10.18632/oncotarget.18395 · Cited by 38
Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer
von Bubnoff, N. C. C. (2017) · Oncology Research and Treatment · doi:10.1159/000478864 · Cited by 38
Angelis, A., Montibeller, G., Hochhauser, D., & Kanavos, P. G. (2017) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-017-0524-3 · Cited by 38
Takayama, Y., Suzuki, K., Muto, Y., Ichida, K., Fukui, T., Kakizawa, N., Ishikawa, H., Watanabe, F., Hasegawa, F., Saito, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25309 · Cited by 38
Lee, H., Na, W., Park, C., Park, K. H., & Shin, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-23766-9 · Cited by 38
Hsu, H., Lapke, N., Wang, C., Lin, P.-Y., You, J. F., Yeh, C. Y., Tsai, W., Hung, H., Chiang, S.-F., Chen, H., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1306 · Cited by 38
Hara, Y., Minami, Y., Yoshimoto, S., Hayashi, N., Yamasaki, A., Ueda, S., Masuko, K., & Masuko, T. (2019) · Cancer Medicine · doi:10.1002/cam4.2689 · Cited by 38
PRSS contributes to cetuximab resistance in colorectal cancer
Tan, Z.-L., Gao, L., Wang, Y., Yin, H., Xi, Y., Wu, X., Shao, Y., Qiu, W., Du, P., Shen, W., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax5576 · Cited by 38
Hemming, M. L., Nathenson, M. J., Lin, J., Mei, S., Du, Z., Malik, K., Mariño‐Enríquez, A., Jagannathan, J. P., Sorger, P. K., Bertagnolli, M. M., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00287 · Cited by 38
Dual-molecular barcode sequencing detects rare variants in tumor and cell free DNA in plasma
Hirotsu, Y., Otake, S., Ohyama, H., Amemiya, K., Higuchi, R., Oyama, T., Mochizuki, H., Goto, T., & Omata, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60361-3 · Cited by 38
Korolkova, O. Y., Widatalla, S. E., Williams, S. D., Whalen, D. S., Beasley, H. K., Ochieng, J., Grewal, T., & Sakwe, A. M. (2020) · Cells · doi:10.3390/cells9081855 · Cited by 38
Liu, Z., Wang, Y., Yuan, S., Wen, F., Liu, J., Zou, L., & Zhang, J. (2021) · Oncology Letters · doi:10.3892/ol.2021.12665 · Cited by 38
Osumi, H., Vecchione, L., Keilholz, U., Vollbrecht, C., Alig, A. H. S., von Einem, J. C., Stahler, A., Striefler, J. K., Kurreck, A., Kind, A. J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.010 · Cited by 38
Liebs, S., Eder, T., Klauschen, F., Schütte, M., Yaspo, M., Keilholz, U., Tinhofer, I., Kidess, E., & Braunholz, D. (2021) · Oncogene · doi:10.1038/s41388-021-01928-w · Cited by 38
Boos, S. L., Loevenich, L. P., Vosberg, S., Engleitner, T., Öllinger, R., Kumbrink, J., Rokavec, M., Michl, M., Greif, P. A., Jung, A., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.10.008 · Cited by 39
Challenges in Using ctDNA to Achieve Early Detection of CancerPreprint
Haque, I. S., & Elemento, O. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/237578 · Cited by 38
Xiong, H., Yu, H., Zhang, J., Fang, L., Wu, D., Lin, X., & Xie, C. (2023) · Military Medical Research · doi:10.1186/s40779-023-00501-8 · Cited by 37
Toxicogenomics and Cancer Susceptibility: Advances with Next-Generation Sequencing
Ning, B., Su, Z., Mei, N., Hong, H., Deng, H., Shi, L. M., Fuscoe, J. C., & Tolleson, W. H. (2014) · Journal of Environmental Science and Health Part C · doi:10.1080/10590501.2014.907460 · Cited by 37
Parsons, H. A., Beaver, J. A., & Park, B. H. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22909-6_11 · Cited by 37
Pharmacogenomics of Platinum-Based Chemotherapy Sensitivity in NSCLC: Toward Precision Medicine
Yin, J., Li, X., Zhou, H., & Liu, Z. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0074 · Cited by 37
Ta, N. L., Chakrabandhu, K., Huault, S., & Hueber, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-30804-z · Cited by 37
Iwahashi, N., Sakai, K., Noguchi, T., Yahata, T., Matsukawa, H., Toujima, S., Nishio, K., & Ino, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-47030-w · Cited by 37
Clifton, K., Rich, T. A., Parseghian, C. M., Raymond, V. M., Dasari, A. N., Pereira, A. A. L., Willis, J. A., Loree, J. M., Bauer, T. M., Chae, Y. K., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00141 · Cited by 37
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症：英文版 · doi:10.1002/cac2.12377 · Cited by 38
Somatic alterations as the basis for resistance to targeted therapies
Blair, B. G., Bardelli, A., & Park, B. H. (2013) · The Journal of Pathology · doi:10.1002/path.4278 · Cited by 36
Self-citationExtended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
Sakai, K., Tsurutani, J., Yamanaka, T., Yoneshige, A., Ito, A., Togashi, Y., Velasco, M. A. D., Terashima, M., Fujita, Y., Tomida, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121891 · Cited by 36
Spindler, K. G. (2016) · Acta Oncologica · doi:10.1080/0284186x.2016.1253861 · Cited by 36
A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy
Gelfo, V., Mazzeschi, M., Grilli, G., Lindzen, M., Santi, S., D’Uva, G., Győrffy, B., Ardizzoni, A., Yarden, Y., & Lauriola, M. (2018) · Cancers · doi:10.3390/cancers10100355 · Cited by 36
Belli, V., Matrone, N., Napolitano, S., Migliardi, G., Cottino, F., Bertotti, A., Trusolino, L., Martinelli, E., Morgillo, F., Ciardiello, D., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1230-z · Cited by 36
Galvano, A., Taverna, S., Badalamenti, G., Incorvaia, L., Castiglia, M., Barraco, N., Passiglia, F., Fulfaro, F., Beretta, G. D., Duro, G., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919874653 · Cited by 36
Current concepts of anti-EGFR targeting in metastatic colorectal cancer
Doleschal, B., Petzer, A., & Rumpold, H. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1048166 · Cited by 36
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015
Aranda, E., Aparicio, J., Alonso, V., García‐Albéniz, X., Alfonso, P. G., Salazar, R., Valladares, M., Vera, R., Viéitez, J. M., & García‐Carbonero, R. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1434-4 · Cited by 36
Metadata
- Authors
- Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., Bencardino, K., Cercek, A., Chen, C.-T., Veronese, S., Zanon, C., Sartore-Bianchi, A., Gambacorta, M., Gallicchio, M., Vakiani, E., Boscaro, V., Medico, E., Weiser, M., Siena, S., Di Nicolantonio, F., Solit, D., & Bardelli, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- Memorial Sloan Kettering Cancer Center (US)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- University of Turin (IT)
- IFOM (IT)
- Corresponding author
- Solit, David
- Bardelli, Alberto
- ORCID
- Venue
- Nature
- Published
- 2012-06
- Volume
- 486
- Issue
- 7404
- Pages
- 532-536
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3927413
- OpenAlex
- W2062109911
- Cited by
- 1,889
- References
- 25
- Citations by year
- 2026: 75 · 2025: 73 · 2024: 81 · 2023: 115 · 2022: 129 · 2021: 138 · 2020: 134 · 2019: 163 · 2018: 161 · 2017: 171 · 2016: 177 · 2015: 163 · 2014: 145 · 2013: 133 · 2012: 28
- FWCI
- 73.66
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- European Commission (259015)
- Associazione Italiana per la Ricerca sul Cancro (5 x mille)
- Regione Piemonte
- National Cancer Institute (R01CA127240, P30CA008748, T32CA009207, R25CA020449)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS mutation, acquired drug resistance, anti-EGFR therapy, cetuximab resistance, colorectal cancer, EGFR, K-ras oncogene, circulating tumor DNA, tumor subclones, MEK inhibition, combination therapy, metastatic colorectal cancer, tumor heterogeneity
- MeSH terms
- Cetuximab, Panitumumab, Alleles, Antibodies, Monoclonal, Humans, Mutation, Promoter Regions, Genetic, Proto-Oncogene Proteins, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease Progression, ras Proteins, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
